University of Texas's MD Anderson Cancer Center: Trametinib Represents Potential New Standard-of-Care for Patients With Recurrent Low-Grade Serous Ovarian Carcinoma
February 04, 2022
February 04, 2022
HOUSTON, Texas, Feb. 4 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Drug showed reduced risk of disease or death and significantly improved progression-free survival
* * *
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care the . . .
* * *
Drug showed reduced risk of disease or death and significantly improved progression-free survival
* * *
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care the . . .